title: Managing drug-drug interactions in an HIV-infected patient receiving antiretrovirals, anti-HCV therapy and carbamazepine: a 'tour de force' for clinical pharmacologists.
authors.affiliation: Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: David.Burger@radboudumc.nl.
authors.forename: David M
authors.initials: DM
authors.lastname: Burger
authors.affiliation: Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Joop E
authors.initials: JE
authors.lastname: Arends
authors.affiliation: Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Birgit S
authors.initials: BS
authors.lastname: Jacobs
authors.affiliation: Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Danielle H M
authors.initials: DH
authors.lastname: van Elst-Laurijsen
authors.affiliation: Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Clara T M M
authors.initials: CT
authors.lastname: de Kanter
authors.affiliation: Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Erik M
authors.initials: EM
authors.lastname: van Maarseveen
authors.affiliation: Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands.
authors.forename: Corrien P W G M
authors.initials: CP
authors.lastname: Verwey-van Wissen
authors.affiliation: Department of Internal Medicine and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
authors.forename: Andy I M
authors.initials: AI
authors.lastname: Hoepelman
mesh_terms: D000927:Anticonvulsants / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D000069446:Atazanavir Sulfate; D002220:Carbamazepine / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D054796:Drug Dosage Calculations; D004347:Drug Interactions; D016903:Drug Monitoring; D004789:Enzyme Activation / Q000187:drug effects; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000821:virology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D019438:Ritonavir / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D000998:Antiviral Agents; D009842:Oligopeptides; D011725:Pyridines; D002220:Carbamazepine; D000069446:Atazanavir Sulfate; C486464:telaprevir; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D019438:Ritonavir